Home・Elenco Azioni・Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.59 3.68

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.15

Massimo

30.85

Metriche Chiave
By Trading Economics
Entrata	8.9M -99M
Vendite	779K 21M
EPS	-1.69
Margine di Profitto	-477.735
Dipendenti	539
EBITDA	23M -98M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+34.25% upside

Dividendi
By Acuity
Utili prossimi	29 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	746M 2.2B
Apertura precedente	27.91
Chiusura precedente	31.59

Notizie sul Sentiment di mercato

By Acuity

50%

151 / 340 Classifica in Healthcare

Agios Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31 lug 2026, 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30 lug 2026, 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29 lug 2026, 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28 lug 2026, 20:02 UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27 lug 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24 lug 2026, 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22 lug 2026, 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21 lug 2026, 19:01 UTC

News

Event

Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Confronto tra pari

Modifica del prezzo

Agios Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

34.25% in crescita

Previsioni per 12 mesi

Media 41 USD 34.25%

Alto 55 USD

Basso 31 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Agios Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Agios Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

151 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.